• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

来自血液鞭毛虫杜氏利什曼原虫的DNA拓扑异构酶IB“催化四联体”的突变研究:天冬氨酸-353和天冬酰胺-221在喜树碱抗性中的作用

Mutational study of the "catalytic tetrad" of DNA topoisomerase IB from the hemoflagellate Leishmania donovani: Role of Asp-353 and Asn-221 in camptothecin resistance.

作者信息

Diaz-González Rosario, Pérez-Pertejo Yolanda, Pommier Yves, Balaña-Fouce Rafael, Reguera Rosa M

机构信息

Departamento de Farmacología y Toxicología (INTOXCAL), Universidad de León, Campus de Vegazana s/n, 24071 León, Spain.

出版信息

Biochem Pharmacol. 2008 Sep 1;76(5):608-19. doi: 10.1016/j.bcp.2008.06.019. Epub 2008 Jul 4.

DOI:10.1016/j.bcp.2008.06.019
PMID:18655776
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9103752/
Abstract

Leishmania donovani, the causative organism for visceral leishmaniasis, contains a unique bisubunit DNA-topoisomerase IB (LdTopIB). The catalytically active enzyme is a heterodimer constituted by a large subunit (LdTopIL) containing a non-conserved N-terminal end and the phylogenetically conserved core domain, whereas the small subunit (LdTopIS) harbors the C-terminal domain with the characteristic tyrosine residue in the active site. Site-directed mutagenesis was used to substitute the basic amino acid (Arg-314, Lys-352, Arg-410 and His-453) of the LdTopIL subunit by the neutral amino acid alanine. The expression of these mutants in a topoisomerase-free yeast strain produced inactive proteins. Similarly, when the Tyr-222 from small subunit, involved in DNA cleavage, was substituted by Phe no topoisomerase activity was detected in yeast overexpressing extracts. In addition two substitutions involved in camptothecin inhibition were also analyzed. Asp-353 located in the core domain of the large subunit and Asn-221 which heads Tyr-222 in the small subunit, were replaced by Ala and Ser, respectively. These mutants were insensitive to the inhibitor; despite they displayed significant relaxation activity.

摘要

杜氏利什曼原虫是内脏利什曼病的病原体,它含有一种独特的双亚基DNA拓扑异构酶IB(LdTopIB)。具有催化活性的酶是一种异源二聚体,由一个大亚基(LdTopIL)和一个小亚基(LdTopIS)组成。大亚基包含一个非保守的N末端和系统发育保守的核心结构域,而小亚基在活性位点带有具有特征性酪氨酸残基的C末端结构域。采用定点诱变将LdTopIL亚基的碱性氨基酸(Arg-314、Lys-352、Arg-410和His-453)替换为中性氨基酸丙氨酸。这些突变体在无拓扑异构酶的酵母菌株中的表达产生了无活性的蛋白质。同样,当参与DNA切割的小亚基中的Tyr-222被Phe取代时,在过表达提取物的酵母中未检测到拓扑异构酶活性。此外,还分析了与喜树碱抑制有关的两个替换。位于大亚基核心结构域的Asp-353和在小亚基中位于Tyr-222上游的Asn-221分别被Ala和Ser取代。这些突变体对抑制剂不敏感;尽管它们表现出显著的松弛活性。

相似文献

1
Mutational study of the "catalytic tetrad" of DNA topoisomerase IB from the hemoflagellate Leishmania donovani: Role of Asp-353 and Asn-221 in camptothecin resistance.来自血液鞭毛虫杜氏利什曼原虫的DNA拓扑异构酶IB“催化四联体”的突变研究:天冬氨酸-353和天冬酰胺-221在喜树碱抗性中的作用
Biochem Pharmacol. 2008 Sep 1;76(5):608-19. doi: 10.1016/j.bcp.2008.06.019. Epub 2008 Jul 4.
2
Deletion study of DNA topoisomerase IB from Leishmania donovani: searching for a minimal functional heterodimer.杜氏利什曼原虫DNA拓扑异构酶IB的缺失研究:寻找最小功能异二聚体
PLoS One. 2007 Nov 14;2(11):e1177. doi: 10.1371/journal.pone.0001177.
3
A pentapeptide signature motif plays a pivotal role in Leishmania DNA topoisomerase IB activity and camptothecin sensitivity.一个五肽特征基序在利什曼原虫DNA拓扑异构酶IB活性和喜树碱敏感性中起关键作用。
Biochim Biophys Acta. 2012 Dec;1820(12):2062-71. doi: 10.1016/j.bbagen.2012.09.005. Epub 2012 Sep 18.
4
N-terminal region of the large subunit of Leishmania donovani bisubunit topoisomerase I is involved in DNA relaxation and interaction with the smaller subunit.杜氏利什曼原虫双亚基拓扑异构酶I大亚基的N端区域参与DNA松弛以及与小亚基的相互作用。
J Biol Chem. 2005 Apr 22;280(16):16335-44. doi: 10.1074/jbc.M412417200. Epub 2005 Feb 12.
5
Discovery of Leishmania donovani topoisomerase IB selective inhibitors by targeting protein-protein interactions between the large and small subunits.通过靶向大、小亚基之间的蛋白-蛋白相互作用发现杜氏利什曼原虫拓扑异构酶 IB 选择性抑制剂。
Biochem Biophys Res Commun. 2021 Sep 10;569:193-198. doi: 10.1016/j.bbrc.2021.07.019. Epub 2021 Jul 10.
6
Leishmania donovani bisubunit topoisomerase I gene fusion leads to an active enzyme with conserved type IB enzyme function.杜氏利什曼原虫双亚基拓扑异构酶I基因融合产生具有保守的IB型酶功能的活性酶。
FEBS J. 2007 Jan;274(1):150-63. doi: 10.1111/j.1742-4658.2006.05572.x.
7
Structural insights on the small subunit of DNA topoisomerase I from the unicellular parasite Leishmania donovani.来自单细胞寄生虫杜氏利什曼原虫的DNA拓扑异构酶I小亚基的结构见解。
Biochimie. 2007 Dec;89(12):1517-27. doi: 10.1016/j.biochi.2007.07.015. Epub 2007 Jul 31.
8
Differential induction of Leishmania donovani bi-subunit topoisomerase I-DNA cleavage complex by selected flavones and camptothecin: activity of flavones against camptothecin-resistant topoisomerase I.选定黄酮类化合物和喜树碱对杜氏利什曼原虫双亚基拓扑异构酶I-DNA切割复合物的差异诱导作用:黄酮类化合物对喜树碱抗性拓扑异构酶I的活性
Nucleic Acids Res. 2006 Feb 18;34(4):1121-32. doi: 10.1093/nar/gkj502. Print 2006.
9
An insight into the mechanism of inhibition of unusual bi-subunit topoisomerase I from Leishmania donovani by 3,3'-di-indolylmethane, a novel DNA topoisomerase I poison with a strong binding affinity to the enzyme.深入了解3,3'-二吲哚甲烷对杜氏利什曼原虫异常双亚基拓扑异构酶I的抑制机制,3,3'-二吲哚甲烷是一种新型DNA拓扑异构酶I抑制剂,对该酶具有很强的结合亲和力。
Biochem J. 2008 Jan 15;409(2):611-22. doi: 10.1042/BJ20071286.
10
The large subunit of Leishmania topoisomerase I functions as the 'molecular steer' in type IB topoisomerase.利什曼原虫拓扑异构酶I的大亚基在IB型拓扑异构酶中起“分子导向”作用。
Mol Microbiol. 2008 Jan;67(1):31-46. doi: 10.1111/j.1365-2958.2007.06002.x. Epub 2007 Nov 25.

引用本文的文献

1
Three different mutations in the DNA topoisomerase 1B in Leishmania infantum contribute to resistance to antitumor drug topotecan.婴儿利什曼原虫DNA拓扑异构酶1B中的三种不同突变导致对抗肿瘤药物拓扑替康产生耐药性。
Parasit Vectors. 2021 Aug 28;14(1):438. doi: 10.1186/s13071-021-04947-4.
2
Trypanosomatids topoisomerase re-visited. New structural findings and role in drug discovery.锥虫拓扑异构酶再探讨。新的结构发现及其在药物研发中的作用。
Int J Parasitol Drugs Drug Resist. 2014 Aug 24;4(3):326-37. doi: 10.1016/j.ijpddr.2014.07.006. eCollection 2014 Dec.
3
Identification and characterization of the regions involved in the nuclear translocation of the heterodimeric leishmanial DNA topoisomerase IB.

本文引用的文献

1
Structural insights on the small subunit of DNA topoisomerase I from the unicellular parasite Leishmania donovani.来自单细胞寄生虫杜氏利什曼原虫的DNA拓扑异构酶I小亚基的结构见解。
Biochimie. 2007 Dec;89(12):1517-27. doi: 10.1016/j.biochi.2007.07.015. Epub 2007 Jul 31.
2
Topoisomerases of kinetoplastid parasites: why so fascinating?动质体寄生虫的拓扑异构酶:为何如此迷人?
Mol Microbiol. 2006 Nov;62(4):917-27. doi: 10.1111/j.1365-2958.2006.05428.x. Epub 2006 Oct 17.
3
The different cleavage DNA sequence specificity explains the camptothecin resistance of the human topoisomerase I Glu418Lys mutant.
鉴定并阐明与双体利什曼原虫 DNA 拓扑异构酶 IB 核转位相关的区域。
PLoS One. 2013 Sep 2;8(9):e73565. doi: 10.1371/journal.pone.0073565. eCollection 2013.
4
Indotecan (LMP400) and AM13-55: two novel indenoisoquinolines show potential for treating visceral leishmaniasis.英地卡丹(LMP400)和 AM13-55:两种新型吲并异喹啉类化合物具有治疗内脏利什曼病的潜力。
Antimicrob Agents Chemother. 2012 Oct;56(10):5264-70. doi: 10.1128/AAC.00499-12. Epub 2012 Jul 30.
5
First total synthesis and antileishmanial activity of (Z)-16-methyl-11-heptadecenoic acid, a new marine fatty acid from the sponge Dragmaxia undata.(Z)-16-甲基-11-十七碳烯酸的全合成及抗利什曼原虫活性:一种来自海绵 Dragmaxia undata 的新型海洋脂肪酸。
Chem Phys Lipids. 2011 Feb;164(2):113-7. doi: 10.1016/j.chemphyslip.2010.11.006. Epub 2010 Dec 1.
6
Total synthesis and antileishmanial activity of the natural occurring acetylenic fatty acids 6-heptadecynoic acid and 6-icosynoic acid.天然存在的炔脂肪酸6-十七碳炔酸和6-二十碳炔酸的全合成及抗利什曼原虫活性
Lipids. 2009 Oct;44(10):953-61. doi: 10.1007/s11745-009-3345-z. Epub 2009 Sep 30.
7
First total synthesis and antiprotozoal activity of (Z)-17-methyl-13-octadecenoic acid, a new marine fatty acid from the sponge Polymastia penicillus.来自海绵多枝多乳头虫的一种新型海洋脂肪酸(Z)-17-甲基-13-十八碳烯酸的首次全合成及抗原生动物活性
Chem Phys Lipids. 2009 Sep;161(1):38-43. doi: 10.1016/j.chemphyslip.2009.06.140. Epub 2009 Jun 13.
不同的切割DNA序列特异性解释了人拓扑异构酶I Glu418Lys突变体对喜树碱的抗性。
Nucleic Acids Res. 2006;34(18):5093-100. doi: 10.1093/nar/gkl670. Epub 2006 Sep 20.
4
DNA topoisomerase I from parasitic protozoa: a potential target for chemotherapy.寄生原生动物的DNA拓扑异构酶I:化疗的潜在靶点。
Biochim Biophys Acta. 2006 Mar-Apr;1759(3-4):117-31. doi: 10.1016/j.bbaexp.2006.03.006. Epub 2006 Apr 26.
5
The structure of the transition state of the heterodimeric topoisomerase I of Leishmania donovani as a vanadate complex with nicked DNA.杜氏利什曼原虫异二聚体拓扑异构酶I与带切口DNA形成的钒酸盐复合物的过渡态结构。
J Mol Biol. 2006 Apr 7;357(4):1202-10. doi: 10.1016/j.jmb.2006.01.022. Epub 2006 Jan 26.
6
Clinical status of agents being developed for leishmaniasis.正在研发的用于治疗利什曼病的药物的临床状况。
Expert Opin Investig Drugs. 2005 Nov;14(11):1337-46. doi: 10.1517/13543784.14.11.1337.
7
The genome of the kinetoplastid parasite, Leishmania major.动质体寄生虫硕大利什曼原虫的基因组。
Science. 2005 Jul 15;309(5733):436-42. doi: 10.1126/science.1112680.
8
Topoisomerase I amino acid substitutions, Gly185Arg and Asp325Glu, confer camptothecin resistance in Leishmania donovani.拓扑异构酶I的氨基酸取代,即甘氨酸185突变为精氨酸和天冬氨酸325突变为谷氨酸,赋予杜氏利什曼原虫对喜树碱的抗性。
Antimicrob Agents Chemother. 2005 Apr;49(4):1441-6. doi: 10.1128/AAC.49.4.1441-1446.2005.
9
Cellular topoisomerase I inhibition and antiproliferative activity by MJ-III-65 (NSC 706744), an indenoisoquinoline topoisomerase I poison.茚并异喹啉拓扑异构酶I抑制剂MJ-III-65(NSC 706744)的细胞拓扑异构酶I抑制作用及抗增殖活性
Mol Pharmacol. 2005 Feb;67(2):523-30. doi: 10.1124/mol.104.003889. Epub 2004 Nov 5.
10
Structure, molecular mechanisms, and evolutionary relationships in DNA topoisomerases.DNA拓扑异构酶的结构、分子机制及进化关系
Annu Rev Biophys Biomol Struct. 2004;33:95-118. doi: 10.1146/annurev.biophys.33.110502.140357.